Sickle Cell Disease Treatment Market Size and Forecasts (2020 – 2030)

Sickle Cell Disease Treatment Market Size and Forecasts (2020 – 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)

Send Enquiry
Item ID: TIPRE00030312 Category: Tags: , ,

$3,185$5,985

Description

The sickle cell disease treatment market is expected to grow from US$ 1.160 billion in 2022 to US$ 4.691 billion by 2030; it is estimated to grow at a CAGR of 19.1% from 2022 to 2030. The market for sickle cell disease treatment is growing due to the increasing prevalence of sickle cell disease and the government and private sector’s initiatives to raise awareness about sickle cell disease. Also, the increasing number of launches of advanced diagnostic tools and rising research activities to provide effective therapeutics are further driving the growth of the market. However, factors such as lack of sickle cell disease treatment options are restraining the market growth.

The treatment plan for sickle cell disease (SCD) can be divided into two categories: maintaining health and treating complications. Sickle cell anemia has genotypic and phenotypic variants that are based on unique mutations in hemoglobin genes. There is a high prevalence of the disease as well as a rise in its severity across the globe. According to the WHO, approximately 5% of the world’s population has genes inhibiting hemoglobin diseases such as sickle cell anemia and thalassemia. According to a study on sickle cell disease published in the National Library of Medicine, more than 300,000 babies are born with severe hemoglobin disorders each year; also, 400,000 newborns are expected to have sickle cell disease by 2050. In addition, according to a published report in 2023 by the American Society of Hematology, the estimated number of people suffering from SCD in the US is approximately 70,000–100,000. Thus, the rising prevalence of malaria and sickle cell disease in different regions across the globe boosts the malaria and sickle cell disease treatment market growth.

Over the years, dedicated pediatric programs and research initiatives have significantly improved patient care and life expectancy. Following are a few foundations that have raised funds to address SCD treatment in the US and around the world.

• American Society of Hematology Foundation seeks to raise US$ 500,000 in private charitable care to develop specific programs that focus on:

o Raising awareness and encouraging action against SCD

o Training and educating hematologists and other healthcare providers who treat SCD patients

o Alleviating funding of SCD programs

o Improving standards of care, research programs, and access to clinical trials for SCD people

o Supporting workforce of hematologists and other health care professionals to optimally treat SCD patients throughout all stages—i.e., early diagnosis through childhood and into adulthood

• Doris Duke Foundation grant awards to support advanced healing methods for SCD, including gene modification and drug therapies to restore hemoglobin function. The annual direct costs to support projects range from US$ 150,000–300,000 plus 10% indirect costs for each of three years. This award aims to support clinical research that will support:

o Advanced gene therapies such as gene addition and genome editing for sickle cell disease in clinics

o Build on globin regulatory mechanisms to restore red blood cell function

o Advance bone marrow transplant procedures to minimize deadliness and improve outcomes

• In August 2021, the Ministry of Tribal Affairs, in collaboration with ICMR, released US$ 7.2 million to the states seeking grants to tackle sickle cell anemia, including screening. The Tribal Research Institute (TRI) Division of the Ministry of Tribal Affairs (MoTA) sanctioned a research study program at Sir Ganga Ram Hospital on sickle cell disease. Also, a project called “’Diagnosis, IEC and Nutri support for sickle cell anemia and Thalassemia affected patients” was undertaken.

• In February 2021, Novartis and the Bill & Melinda Gates Foundation collaborated to determine and develop an accessible in vivo gene therapy for sickle cell disease. The partnership, funded with US$ 7.28 million, aims to develop a treatment that is affordable and simple enough to be used in low-resource areas with a high prevalence of SCD, particularly sub-Saharan Africa, where about 80% of affected people worldwide are located. The collaboration hopes to create an off-the-shelf treatment that can bypass some of the in vivo steps involved in current gene therapy approaches to treat SCD, which are costly, complex, and crafted for individual patients.

• In March 2022, a team of international researchers received a grant of US$ 3 million from the National Institutes of Health (NIH) to sequence the whole genetic code of children with sickle cell disease in Ghana. By analyzing the whole DNA sequence of 500 Ghanaian children with SCD, the researchers hope to identify potential genetic modifiers of the disease that will help improve the management and care of patients. These children are the participants in the Sickle Cell Disease Genomics Network of Africa (SickleGenAfrica). A US$ 5.4-million, NIH-funded international project led by Ofori-Acquah also focused on understanding how genetics influence SCD progression in Africans.

Treatment-Based Insights

The sickle cell disease treatment market is segmented based on treatment into generic drugs and originators. Originators segment held the largest market share in 2022. Sickle cell disease is an inherited blood disorder marked by defective hemoglobin. It inhibits the capability of hemoglobin in red blood cells to carry oxygen.

Route of Administration-Based Insights

Based on route of administration, the malaria treatment market is bifurcated into oral and parenteral & intravenous. The oral segment accounted for the largest share of the market in 2022; however, the parenteral segment is expected to register the highest CAGR during the forecast period. Oral drug delivery is the most preferred and suitable route of drug administration as it offers high patient compliance, non-invasiveness, least sterility constraints, cost-effectiveness, flexibility in the design of dosage form and ease in the manufacturing process. Benefits such as ease of administration and long-term cost efficiency are major factors fueling the adoption of oral drugs.

Distribution Channel-Based Insights

Based on distribution channels, the malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment accounted for the largest share of the market in 2022; however, the online pharmacies segment is expected to register the highest CAGR during the forecast period.

A few of the major primary and secondary sources referred to while preparing the report on the malaria treatment market are the World Health Organization (WHO), the US Census Bureau, and CDC, among others.

Summary Info

Industry:

Number of pages:

Pricing options:

, ,

Publishing status:

Geographical coverage:

Year of Publication:

Government and Private Sector’s Initiatives to Raise Awareness About SCD to Drive Global Sickle Cell Disease Treatment Market During 2022–2030

According to our latest study on ” Sickle Cell Disease Treatment Market Forecast to 2030 – Global Analysis –Treatment, Route of Administration, and Distribution Channel,” the market is expected to grow from US$ 1.160 billion in 2022 to US$ 4.691 billion by 2030; it is estimated to grow at a CAGR of 19.1% during 2022–2030. The market growth is primarily attributed to increasing prevalence of sickle cell disease and the government and private sector’s initiatives to raise awareness about sickle cell disease. However, lack of sickle cell disease treatment options are hindering the market growth.

Sickle cell disease awareness campaigns help enhance the knowledge of the population regarding the disease, thereby promoting healthcare services through intersectoral collaboration and social support. Governments of several countries are taking various initiatives to create awareness and conduct research for the development of new SCD drugs and vaccines. Governments of various countries across the globe with a high prevalence of sickle cell disease are deploying various strategies to eradicate the diseases by improving access to healthcare services, including treatment options, to the people. To overcome this challenge, the R&D of new medicines is considered the best strategy; as a result, the SCD drug/vaccine pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities related to the treatment of sickle cell disease.

A few SCD drugs/vaccines that are under clinical development are mentioned in the table below:

Table 1. Sickle Cell Disease Drugs/Vaccine/Compounds Under Clinical Development

Drug Developer Clinical Trial Stage

Inclacumab Pfizer Phase III

Voxelotor Pfizer Phase III

GBT021601 Pfizer Phase II

PF-07209326 Pfizer Phase II

RG6107 Roche Phase II

GSK4172239D GSK Phase I

BEAM¬–101 Beam Therapeutics Phase I/II

HGB-206 Bluebird Bio, Inc. Phase I/II

HGB-210 Bluebird Bio, Inc. Phase III

ALXN1820 Alexion Phase II

NCT05714969 Takeda Pharmaceutical Company Limited Phase 2b

NCT03997760 Takeda Pharmaceutical Company Limited Phase I

Source: Company Website,the research team Analysis

Therefore, the growing number of SCD drugs/vaccines that are under clinical development are expected to boost the market growth in the future.

Increasing Prevalence of Sickle Cell Disease to Bolster Sickle Cell Disease Treatment Market Growth

The treatment plan for sickle cell disease (SCD) can be divided into two categories: maintaining health and treating complications. Sickle cell anemia has genotypic and phenotypic variants that are based on unique mutations in hemoglobin genes. There is a high prevalence of the disease as well as a rise in its severity across the globe. According to the WHO, approximately 5% of the world’s population has genes inhibiting hemoglobin diseases such as sickle cell anemia and thalassemia. According to a study on sickle cell disease published in the National Library of Medicine, more than 300,000 babies are born with severe hemoglobin disorders each year; also, 400,000 newborns are expected to have sickle cell disease by 2050. In addition, according to a published report in 2023 by the American Society of Hematology, the estimated number of people suffering from SCD in the US is approximately 70,000–100,000. Thus, the rising prevalence of sickle cell disease in different regions across the globe boosts the sickle cell disease treatment market growth.

Novartis AG, Pfizer Inc, Emmaus Life Sciences Inc, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Siklos, Mylan NV, Taj Pharmaceuticals Limited, and Apotex are among the leading companies operating in the sickle cell disease treatment market.

Sickle Cell Disease Treatment Market, by Region, 2022 (%)

Source:the research team Analysis

?

Based on treatment, the sickle cell disease treatment market is segmented into generic drugs and originators. Based on route of administration, the sickle cell disease treatment market is bifurcated into oral and parenteral. Based on distribution channel, the sickle cell disease treatment market is divided into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. By geography, the sickle cell disease treatment market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, Nigeria, Congo, Tanzania, Uganda, Ghana, Kenya, Zambia, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

– Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific frozen waffles market.
– Highlights key business priorities in order to assist companies to realign their business strategies.
– the key findings and recommendations highlight crucial progressive industry trends in Asia Pacific frozen waffles market, thereby allowing players across the value chain to develop effective long-term strategies.
– develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
– Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
– Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 South & Central America Stem Cell Therapy Market – By Type
1.3.2 South & Central America Stem Cell Therapy Market – By Treatment
1.3.3 South & Central America Stem Cell Therapy Market – By Application
1.3.4 South & Central America Stem Cell Therapy Market – By End User
1.3.5 South & Central America Stem Cell Therapy Market – By Country
2. South & Central America Stem Cell Therapy Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Stem Cell Therapy Market– Market Landscape
4.1 Overview
4.2 South & Central America PEST Analysis
4.3 Experts Opinion
5. South & Central America Stem Cell Therapy Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Research Activities Related to Stem Cell Therapy for Effective Disease Management
5.1.2 Growing Prevalence of Cancer
5.2 Market Restraints
5.2.1 High Cost of Approved Treatments
5.3 Market Opportunities
5.3.1 Use of Induced Pluripotent Stem Cells in Regenerative Medicines
5.4 Future Trends
5.4.1 Research Activities and Product Innovations
5.5 Impact Analysis
6. Stem Cell Therapy Market – South & Central America Analysis
6.1 South & Central America Stem Cell Therapy Market Revenue Forecast and Analysis
7. South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 – by Type
7.1 Overview
7.2 South & Central America Stem Cell Therapy Market Revenue Share, by Type 2021 & 2028 (%)
7.3 Adult Stem Cell Therapy
7.3.1 Overview
7.3.2 Adult Stem Cell Therapy: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
7.3.3 Hematopoietic Stem Cell Therapy
7.3.3.1 Overview
7.3.3.2 Hematopoietic Stem Cell Therapy: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
7.3.4 Umbilical Cord Stem Cell Therapy
7.3.4.1 Overview
7.3.4.2 Umbilical Cord Stem Cell Therapy: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
7.3.5 Neuronal Stem Cell Therapy
7.3.5.1 Overview
7.3.5.2 Neuronal Stem Cell Therapy: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
7.3.6 Mesenchymal Stem Cell
7.3.6.1 Overview
7.3.6.2 Mesenchymal Stem Cell: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Embryonic Stem Cell Therapy
7.4.1 Overview
7.4.2 Embryonic Stem Cell Therapy: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Induced Pluripotent Stem Cell Therapy
7.5.1 Overview
7.5.2 Induced Pluripotent Stem Cell Therapy: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Other Stem Cell Therapy
7.6.1 Overview
7.6.2 Other Stem Cell Therapy: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
8. South & Central America Stem Cell Therapy Market Analysis and Forecasts to 2028 – by Treatment
8.1 Overview
8.2 South & Central America Stem Cell Therapy Market, by Treatment 2021 & 2028 (%)
8.3 Allogeneic
8.3.1 Overview
8.3.2 Allogeneic: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Autologous
8.4.1 Overview
8.4.2 Autologous: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
9. South & Central America Stem Cell Therapy Market Analysis and Forecasts to 2028 – by Application
9.1 Overview
9.2 South & Central America Stem Cell Therapy Market, by Application 2021 & 2028 (%)
9.3 Musculoskeletal
9.3.1 Overview
9.3.2 Musculoskeletal: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Dermatology
9.4.1 Overview
9.4.2 Dermatology: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Cardiology
9.5.1 Overview
9.5.2 Cardiology: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
9.6 Drug Discovery and Development
9.6.1 Overview
9.6.2 Drug Discovery and Development: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
9.7 Other Applications
9.7.1 Overview
9.7.2 Other Applications: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
10. South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 – by End User
10.1 Overview
10.2 South & Central America Stem Cell Therapy Market Revenue Share, by End User 2021 & 2028 (%)
10.3 Academic & Research Institutes
10.3.1 Overview
10.3.2 Academic & Research Institutes: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Hospitals & Specialty Clinics
10.4.1 Overview
10.4.2 Hospitals & Specialty Clinics: South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 (US$ Million)
11. South & Central America Stem Cell Therapy Market – Revenue and Forecast to 2028 – Country Analysis
11.1 Overview
11.1.1 South and Central America: Stem Cell Therapy Market, by Country, 2021 & 2028(%)
11.1.1.1 Brazil: Stem Cell Therapy Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.1.1 Brazil: Stem Cell Therapy Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.1.2 Brazil: Stem Cell Therapy Market, by Type, 2019-2028 (USD Million)
11.1.1.1.2.1 Brazil: Stem Cell Therapy Market, by Adult Stem Cell Therapy, 2019-2028 (USD Million)
11.1.1.1.3 Brazil: Stem Cell Therapy Market, by Treatment, 2019-2028 (USD Million)
11.1.1.1.4 Brazil: Stem Cell Therapy Market, by Application, 2019-2028 (USD Million)
11.1.1.1.5 Brazil: Stem Cell Therapy Market, by End User , 2019-2028 (USD Million)
11.1.1.2 Argentina: Stem Cell Therapy Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.2.1 Argentina: Stem Cell Therapy Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.2.2 Argentina: Stem Cell Therapy Market, by Type, 2019-2028 (USD Million)
11.1.1.2.2.1 Argentina: Stem Cell Therapy Market, by Adult Stem Cell Therapy, 2019-2028 (USD Million)
11.1.1.2.3 Argentina: Stem Cell Therapy Market, by Treatment, 2019-2028 (USD Million)
11.1.1.2.4 Argentina: Stem Cell Therapy Market, by Application, 2019-2028 (USD Million)
11.1.1.2.5 Argentina: Stem Cell Therapy Market, by End User , 2019-2028 (USD Million)
11.1.1.3 Rest of South and Central America: Stem Cell Therapy Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.3.1 Rest of South and Central America: Stem Cell Therapy Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.3.2 Rest of South and Central America: Stem Cell Therapy Market, by Type, 2019-2028 (USD Million)
11.1.1.3.2.1 Rest of South and Central America: Stem Cell Therapy Market, by Adult Stem Cell Therapy, 2019-2028 (USD Million)
11.1.1.3.3 Rest of South and Central America: Stem Cell Therapy Market, by Treatment, 2019-2028 (USD Million)
11.1.1.3.4 Rest of South and Central America: Stem Cell Therapy Market, by Application, 2019-2028 (USD Million)
11.1.1.3.5 Rest of South and Central America: Stem Cell Therapy Market, by End User , 2019-2028 (USD Million)
12. South & Central America Stem Cell Therapy Market–Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 TiGenix NV (Takeda Pharmaceutical Company Limited)
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 NuVasive Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Lonza Group AG
13.3.1 Business Description
13.3.2 Products and Services
13.3.3 Financial Overview
13.3.4 SWOT Analysis
13.3.5 Key Developments
13.4 Smith & Nephew Plc
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
14. Appendix
14.1 About
14.2 Glossary of Terms

LIST OF TABLES

LIST OF FIGURES

The List of Companies – Sickle Cell Disease Treatment Market
– Novartis AG
– Pfizer Inc
– Emmaus Life Sciences Inc
– Teva Pharmaceutical Industries Ltd.
– Bristol-Myers Squibb Company
– Siklos
– Mylan NV
– Taj Pharmaceuticals Limited
– Apotex

Reviews

There are no reviews yet.

Be the first to review “Sickle Cell Disease Treatment Market Size and Forecasts (2020 – 2030)”